Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Neurocrine Biosciences stock price, quote, forecast and news

NBIX
US64125C1099
900964

Price

121.21
Today +/-
-1.20
Today %
-1.09 %
P

Neurocrine Biosciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Neurocrine Biosciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Neurocrine Biosciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Neurocrine Biosciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Neurocrine Biosciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Neurocrine Biosciences Stock Price History

DateNeurocrine Biosciences Price
9/5/2024121.21 undefined
9/4/2024122.54 undefined
9/3/2024125.10 undefined
8/30/2024127.06 undefined
8/29/2024128.43 undefined
8/28/2024123.76 undefined
8/27/2024152.55 undefined
8/26/2024152.27 undefined
8/23/2024152.81 undefined
8/22/2024152.57 undefined
8/21/2024150.89 undefined
8/20/2024149.59 undefined
8/19/2024148.24 undefined
8/16/2024145.01 undefined
8/15/2024147.77 undefined
8/14/2024146.69 undefined
8/13/2024150.70 undefined
8/12/2024147.29 undefined
8/9/2024147.32 undefined
8/8/2024146.73 undefined

Neurocrine Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Neurocrine Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Neurocrine Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Neurocrine Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Neurocrine Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Neurocrine Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Neurocrine Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Neurocrine Biosciences’s growth potential.

Neurocrine Biosciences Revenue, EBIT and net profit per share

DateNeurocrine Biosciences RevenueNeurocrine Biosciences EBITNeurocrine Biosciences Net Income
2029e4.12 B undefined0 undefined1.55 B undefined
2028e3.92 B undefined1.81 B undefined1.55 B undefined
2027e3.45 B undefined1.4 B undefined1.32 B undefined
2026e3.25 B undefined1.19 B undefined946.5 M undefined
2025e2.77 B undefined857.79 M undefined684.76 M undefined
2024e2.37 B undefined575.02 M undefined429.34 M undefined
20231.89 B undefined394.8 M undefined249.7 M undefined
20221.49 B undefined250.7 M undefined154.5 M undefined
20211.13 B undefined207.8 M undefined89.6 M undefined
20201.05 B undefined327.5 M undefined407.3 M undefined
2019788.1 M undefined226.6 M undefined37 M undefined
2018451.2 M undefined36.9 M undefined21.1 M undefined
2017161.6 M undefined-131.4 M undefined-142.5 M undefined
201615 M undefined-147.4 M undefined-141.1 M undefined
201519.8 M undefined-94.2 M undefined-88.9 M undefined
20140 undefined-64.4 M undefined-60.5 M undefined
20132.9 M undefined-49.7 M undefined-46.1 M undefined
201253.1 M undefined2.5 M undefined5 M undefined
201177.4 M undefined34 M undefined37.6 M undefined
201033.5 M undefined-10.9 M undefined-8 M undefined
20093 M undefined-45.2 M undefined-51 M undefined
20084 M undefined-69.5 M undefined-88.6 M undefined
20071.2 M undefined-111.3 M undefined-207.3 M undefined
200639.2 M undefined-103.8 M undefined-107.2 M undefined
2005123.9 M undefined-25.1 M undefined-22.2 M undefined
200485.2 M undefined-52.3 M undefined-45.8 M undefined

Neurocrine Biosciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0000.010.020.030.020.020.010.040.020.140.090.120.040000.030.080.05000.020.020.160.450.791.051.131.491.892.372.773.253.453.924.12
----216.6736.84-38.46--12.50192.86-56.10672.22-38.8544.71-68.29-97.44300.00-25.001,000.00133.33-31.17-96.23---21.05973.33180.1274.7232.618.4231.3326.8125.5416.8417.386.1213.605.18
-------------------------99.3898.8998.9899.0498.7698.4597.88------
00000000000000000000000000.160.450.781.041.121.471.85000000
0-0-0.01-000-0.01-0.02-0.04-0.04-0.1-0.06-0.05-0.03-0.1-0.11-0.07-0.05-0.010.030-0.05-0.06-0.09-0.15-0.130.040.230.330.210.250.390.580.861.191.41.810
----66.6715.793.85-75.00-118.75-250.00-104.88-572.22-41.73-61.18-20.33-264.10-11,100.00-1,725.00-1,500.00-30.3044.163.77-2,450.00--494.74-980.00-81.377.9828.6831.2918.2716.8020.8824.2730.9636.6340.5246.31-
0-0-0.01-00.010.01-0.02-0.02-0.03-0.04-0.09-0.03-0.05-0.02-0.11-0.21-0.09-0.05-0.010.040.01-0.05-0.06-0.09-0.14-0.140.020.040.410.090.150.250.430.680.951.321.551.55
--75.00-57.14-266.67--500.00-20.0075.0028.57161.11-68.0950.00-51.11386.3693.46-57.49-42.05-84.31-562.50-86.49-1,020.0030.4346.6760.230.71-114.7976.191,000.00-78.1373.0361.6972.2959.4438.3039.9617.15-0.26
1.26.110.911.716.118.218.119.122.12630.532.436.236.837.73838.439.152.856.366.96774.684.586.788.195.495.797.897.998.9101000000
--------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Neurocrine Biosciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Neurocrine Biosciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (B)TOTAL CAPITAL (B)
199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                           
0.020.020.070.080.060.090.160.320.240.450.30.270.180.180.080.050.130.130.170.150.190.380.310.520.650.670.80.710.991.03
011.30.41.41.569.90.213.78.20.97.20004.51.914.1000031.157.4126.6157.1185.5350439.3
000000000000000000000000000000
00000000000000000000000010.917.32830.535.138.3
0.30.20.80.91.62.31.81.63.154.55.43.93.50.91.91.71.52.22.74.44.93.17.918.616.630.145.579.197.8
0.020.020.070.080.070.090.170.330.250.470.310.280.190.180.080.060.130.130.190.150.20.380.310.550.740.831.020.971.451.61
2.72.83.58.810.911.211.312.114.156.2102.299.391.482.66.22.71.51.61.91.82.53.46.310.833.9116.3127.4155.8145.6347.3
0003.31.400000000021.16.43.700.5037.582.543.5247.4216355.5265.3624.4401.5849.4
000000000000000000000000000000
0.70.91.41.210.60.40.20000000000000000000037.235.5
000000000000000000000000000000
0.40.40.92.21.62.61.92.64.326.9103.2104.5104.611.19.56.36.14.34.34.44.84.84.94.55.53.2325.8319.5330.9412.2
000.010.020.010.010.010.010.020.080.210.20.20.090.040.020.010.010.010.010.040.090.050.260.260.480.721.10.921.64
0.020.020.080.090.080.110.190.350.270.560.520.480.390.280.120.070.140.140.20.150.240.470.370.820.991.311.732.072.373.25
                                                           
31.535.683.300000000000000.10.10.10.10.10.10.10.10.10.10.10.10.10.1
-0-0-00.090.10.140.230.420.420.620.670.690.720.730.740.760.780.780.870.891.041.341.371.571.661.771.852.012.122.38
-12.5-15.9-10-4.9-24.9-41.7-70.5-107.4-201.9-232.2-278-300.1-407.4-614.7-703.3-754.3-762.3-724.7-719.7-765.8-826.3-915.2-1,056.3-1,198.9-1,177.8-1,132.7-725.4-635.8-406.8-157.1
0-0.3-0.4-0.4-0.2-0.40.2-1.92.30.9-2.2-1.50.1-0.2-1.61.20-0.100-0.3-1-0.3-1.9-1.91.41.8-1.7-7.97
00000-0.3000000000000000000000000
0.020.020.070.080.070.10.160.310.220.390.390.390.310.120.0400.020.060.150.120.210.420.310.370.480.641.131.371.712.23
0.70.80.81.82.52.41.11.521.35.43.43.23.81.62.20.81.10.90.10.22.65.15.638.446.297.6142.8235.7318.3
0.60.91.42.22.1511.115.822.255.119.817.912.421.710.96.28.68.58.1811.51921.147.934.472.781.499.5129.3162.5
00.51.12.10.20.21.25.45.749.727.76.502.913.611.543.437.56.63.63.94.14.20.915.437.57.53.53.33.9
0000000000000000000000000408.80000
0.50.70.80.90.811.62.12.746.75.84.51.500000000000000169.4170.1
1.82.94.175.68.61524.832.6110.159.633.620.129.926.119.952.847.115.611.715.625.730.454.488.2565.2186.5245.8537.7654.8
1.71.60.80.72.22.12.33.65.332.559.553.649.2108.7000000000369.6388.50317.9335.100
000000000000000000000000000000
00.20.310.82.15.57.64.521.46.45.75.719.355.346.972.331.22622.618.724.619.821.435.7103.8104.1117.6123.2364.6
1.71.81.11.734.27.811.29.853.965.959.354.912855.346.972.331.22622.618.724.619.8391424.2103.8422452.7123.2364.6
000.010.010.010.010.020.040.040.160.130.090.080.160.080.070.130.080.040.030.030.050.050.450.510.670.610.70.661.02
0.020.020.080.090.080.110.190.350.270.560.520.480.390.280.120.070.140.140.20.150.240.470.370.820.991.311.732.072.373.25
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Neurocrine Biosciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Neurocrine Biosciences's financial health and stability.

Assets

Neurocrine Biosciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Neurocrine Biosciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Neurocrine Biosciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Neurocrine Biosciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-4-7-355-20-16-28-36-94-30-45-22-107-207-88-51-8375-46-60-88-141-142213740789154249
000111222337101097310000112478101521
000000000000000000000000000-310419-56
00001-22011317-243-1116-11-13-9-4-1312185-8-10-3716-6728
0000292710-146-36-228121251368-31-211021695697136182261269390341
0000000000014330000000006111111863
0000000000000000000000000001551451
-3-7-2611-10-10-18-21-7937-100-30-99-59-74-53490-35-29-47-38-106-94101152228256339389
000-1-6-3-2-2-3-5-50-103-7-30-1000-10-1-1-4-6-24-14-10-23-16-28
-1-130-48-74-21-75-16-45-186189120204412-54-3-345-105-195113-251-242-2114-130-177-467
0-131-4608-19-73-12-40-13612116123214512-54-2-335-103-193117-244-218-19615-106-160-438
0000000000000000000000000000000
00000100121429-6-556-10000000050200-1860-2790
234347004193179319661715009210835138277213292729274465
233346014194181521136101057-1921083513827725162927-15727-23465
-------------------------------
0000000000000000000000000000000
19-17144-490142-11961-44-113118-31-3116-313-19-13439171-112-3174153-73-11
-3.9-7.1-2.45.14.6-14.5-12.4-21-25.7-85.2-13.3-203.1-38-102.4-59.9-75.5-53.149.6-1.5-36.3-30.1-48.7-39.9-110.3-101.276.6137.4217.6233.1322.9361.6
0000000000000000000000000000000

Neurocrine Biosciences stock margins

The Neurocrine Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Neurocrine Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Neurocrine Biosciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Neurocrine Biosciences's sales revenue. A higher gross margin percentage indicates that the Neurocrine Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Neurocrine Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Neurocrine Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Neurocrine Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Neurocrine Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Neurocrine Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Neurocrine Biosciences Margin History

Neurocrine Biosciences Gross marginNeurocrine Biosciences Profit marginNeurocrine Biosciences EBIT marginNeurocrine Biosciences Profit margin
2029e97.9 %0 %37.55 %
2028e97.9 %46.31 %39.6 %
2027e97.9 %40.52 %38.41 %
2026e97.9 %36.62 %29.12 %
2025e97.9 %30.99 %24.74 %
2024e97.9 %24.26 %18.12 %
202397.9 %20.92 %13.23 %
202298.44 %16.84 %10.38 %
202198.74 %18.33 %7.9 %
202099.03 %31.31 %38.94 %
201999.06 %28.75 %4.69 %
201898.94 %8.18 %4.68 %
201799.26 %-81.31 %-88.18 %
201697.9 %-982.67 %-940.67 %
201597.9 %-475.76 %-448.99 %
201497.9 %0 %0 %
201397.9 %-1,713.79 %-1,589.66 %
201297.9 %4.71 %9.42 %
201197.9 %43.93 %48.58 %
201097.9 %-32.54 %-23.88 %
200997.9 %-1,506.67 %-1,700 %
200897.9 %-1,737.5 %-2,215 %
200797.9 %-9,275 %-17,275 %
200697.9 %-264.8 %-273.47 %
200597.9 %-20.26 %-17.92 %
200497.9 %-61.38 %-53.76 %

Neurocrine Biosciences Stock Sales Revenue, EBIT, Earnings per Share

The Neurocrine Biosciences earnings per share therefore indicates how much revenue Neurocrine Biosciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Neurocrine Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Neurocrine Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Neurocrine Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Neurocrine Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Neurocrine Biosciences Revenue, EBIT and net profit per share

DateNeurocrine Biosciences Sales per ShareNeurocrine Biosciences EBIT per shareNeurocrine Biosciences Earnings per Share
2029e40.8 undefined0 undefined15.32 undefined
2028e38.79 undefined0 undefined15.36 undefined
2027e34.15 undefined0 undefined13.11 undefined
2026e32.18 undefined0 undefined9.37 undefined
2025e27.41 undefined0 undefined6.78 undefined
2024e23.47 undefined0 undefined4.25 undefined
202318.68 undefined3.91 undefined2.47 undefined
202215.05 undefined2.53 undefined1.56 undefined
202111.58 undefined2.12 undefined0.92 undefined
202010.69 undefined3.35 undefined4.16 undefined
20198.24 undefined2.37 undefined0.39 undefined
20184.73 undefined0.39 undefined0.22 undefined
20171.83 undefined-1.49 undefined-1.62 undefined
20160.17 undefined-1.7 undefined-1.63 undefined
20150.23 undefined-1.11 undefined-1.05 undefined
20140 undefined-0.86 undefined-0.81 undefined
20130.04 undefined-0.74 undefined-0.69 undefined
20120.79 undefined0.04 undefined0.07 undefined
20111.37 undefined0.6 undefined0.67 undefined
20100.63 undefined-0.21 undefined-0.15 undefined
20090.08 undefined-1.16 undefined-1.3 undefined
20080.1 undefined-1.81 undefined-2.31 undefined
20070.03 undefined-2.93 undefined-5.46 undefined
20061.04 undefined-2.75 undefined-2.84 undefined
20053.37 undefined-0.68 undefined-0.6 undefined
20042.35 undefined-1.44 undefined-1.27 undefined

Neurocrine Biosciences business model

Neurocrine Biosciences Inc was founded in 1992 by Kevin Gorman and has been headquartered in San Diego, California since then. The company focuses on the discovery, development, and commercialization of novel therapy options for patients with neurological and endocrine disorders. Neurocrine Biosciences' business model is based on collaboration with other pharmaceutical companies, academic partners, and clinical research organizations to conduct both preclinical and clinical trials. The company has a strong commitment to collaboration and partnership with research institutions to bring cutting-edge scientific innovations. The company's work focuses on the discovery and development of new molecules and drugs that can improve patients' lives. Neurocrine has several divisions within its business model. The neurology division is involved in the development of drugs for the treatment of neurological disorders such as Parkinson's disease, restless leg syndrome (RLS), and Tourette syndrome. In the endocrinology division, the company focuses on developing therapies for conditions such as diabetes, hypothyroidism, and syndrome X. Neurocrine Biosciences' most well-known product is Ingrezza, a medication for the treatment of uncontrollable movement disorders in patients with tardive dyskinesia. The development of Ingrezza was a significant milestone for the company as it is the first and only medication on the market specifically approved for this condition. Another product currently being developed by Neurocrine Biosciences is NBI-74788, an oral therapy being developed for the treatment of the classical form of congenital adrenal hyperplasia (CAH). CAH is a rare endocrine disorder that can impair the growth and development of children. Currently, there is no approved therapy for the classical form of CAH, so a new medication can have a massive impact on the quality of life for patients with this condition. Overall, Neurocrine Biosciences has several promising products in the pipeline that can help improve the lives of millions of patients with neurological and endocrine disorders. In terms of corporate history, Neurocrine Biosciences has undergone some significant developments in recent years. In 2017, the company received approval from the U.S. Food and Drug Administration (FDA) for Ingrezza, which was a major milestone for the company. Also in 2017, the company announced a partnership with BIAL, an international pharmaceutical company based in Portugal. This partnership focuses on the joint development and commercialization of Opicapone, a new medication for the treatment of Parkinson's disease. Overall, Neurocrine Biosciences has established itself as an innovative and dedicated company in the biotech industry. The company is known for its collaboration with other companies and research institutions, which is crucial in the fast-paced world of biotechnology. With a strong pipeline of products for the treatment of neurological and endocrine disorders, Neurocrine Biosciences will continue to play a significant role in the industry. Neurocrine Biosciences is one of the most popular companies on Eulerpool.com.

Neurocrine Biosciences SWOT Analysis

Strengths

  • Robust pipeline of innovative drugs in various stages of development.
  • Strong intellectual property portfolio providing competitive advantage.
  • Experienced management team with expertise in drug discovery and development.

Weaknesses

  • Heavy reliance on a few key products for revenue generation.
  • Vulnerability to regulatory approvals and clinical trial results.
  • Limited geographic presence with most operations concentrated in the United States.

Opportunities

  • Increasing demand for innovative therapies in the pharmaceutical market.
  • Potential for strategic partnerships and collaborations to expand market reach.
  • Growing prevalence of target diseases providing a larger patient population.

Threats

  • Intense competition from both established pharmaceutical companies and emerging biotech startups.
  • Stringent regulatory environment increasing the time and cost of drug development.
  • Uncertainty in reimbursement policies and pricing pressures affecting profitability.

Neurocrine Biosciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Neurocrine Biosciences historical P/E ratio, EBIT, and P/S ratio.

Neurocrine Biosciences shares outstanding

The number of shares was Neurocrine Biosciences in 2023 — This indicates how many shares 101 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Neurocrine Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Neurocrine Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Neurocrine Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Neurocrine Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Neurocrine Biosciences.

Neurocrine Biosciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20241.08 0.63  (-41.42 %)2024 Q2
3/31/20241.03 0.42  (-59.17 %)2024 Q1
12/31/20231.17 1.44  (23.28 %)2023 Q4
9/30/20230.99 0.82  (-16.79 %)2023 Q3
6/30/20230.79 0.95  (19.84 %)2023 Q2
3/31/20230.13 -0.79  (-697.13 %)2023 Q1
12/31/20221.18 0.88  (-25.33 %)2022 Q4
9/30/20220.81 0.69  (-14.9 %)2022 Q3
6/30/20220.61 -0.18  (-129.58 %)2022 Q2
3/31/20220.36 0.14  (-60.96 %)2022 Q1
1
2
3
4
5
...
11

Eulerpool ESG Scorecard© for the Neurocrine Biosciences stock

Eulerpool World ESG Rating (EESG©)

66/ 100

🌱 Environment

68

👫 Social

92

🏛️ Governance

38

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees53
Percentage of women in management—
Percentage of Asian employees15.8
Share of Asian management—
Percentage of Hispanic/Latino employees7.4
Hispano/Latino Management share—
Percentage of Black employees3.1
Black Management Share—
Percentage of white employees66.9
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Neurocrine Biosciences list of shareholders

%
Name
Stocks
Change
Date
9.58 % The Vanguard Group, Inc.9,671,524150,48512/31/2023
4.02 % State Street Global Advisors (US)4,063,336226,82912/31/2023
2.41 % Bellevue Asset Management AG2,430,500-153,05012/31/2023
10.45 % BlackRock Institutional Trust Company, N.A.10,552,53585,53312/31/2023
1.97 % Renaissance Technologies LLC1,988,546398,38212/31/2023
1.61 % Geode Capital Management, L.L.C.1,623,12468,49412/31/2023
1.54 % Janus Henderson Investors1,551,367-165,68712/31/2023
1.49 % JP Morgan Asset Management1,507,353-108,68012/31/2023
1.38 % T. Rowe Price Associates, Inc.1,398,011305,90612/31/2023
1.38 % Point72 Asset Management, L.P.1,391,970-1,198,26412/31/2023
1
2
3
4
5
...
10

Neurocrine Biosciences Executives and Management Board

Dr. Kevin Gorman65
Neurocrine Biosciences Chief Executive Officer, Director (since 2003)
Compensation 11.9 M
Dr. Jude Onyia59
Neurocrine Biosciences Chief Scientific Officer
Compensation 7.58 M
Mr. Eric Benevich57
Neurocrine Biosciences Chief Commercial Officer
Compensation 5.81 M
Dr. Adm. Eiry Roberts59
Neurocrine Biosciences Chief Medical Officer
Compensation 5.74 M
Dr. Kyle Gano50
Neurocrine Biosciences Chief Business Development and Strategy Officer
Compensation 5.42 M
1
2
3
4

Most common questions regarding Neurocrine Biosciences

What values and corporate philosophy does Neurocrine Biosciences represent?

Neurocrine Biosciences Inc represents values of innovation, dedication, and patient-centered care. As a leading biopharmaceutical company, Neurocrine is committed to discovering and developing innovative treatments for patients with neurological and endocrine disorders. The company's corporate philosophy focuses on advancing science to improve the lives of individuals suffering from these conditions. Neurocrine takes pride in its research-driven approach and collaboration with healthcare professionals to deliver effective therapies. By combining cutting-edge technology, scientific expertise, and a patient-centric mindset, Neurocrine Biosciences Inc aims to provide solutions that enhance the quality of life for patients in need.

In which countries and regions is Neurocrine Biosciences primarily present?

Neurocrine Biosciences Inc primarily operates in the United States, with its headquarters located in San Diego, California. As a biopharmaceutical company, Neurocrine Biosciences is primarily focused on discovering, developing, and commercializing innovative therapeutics for neurological and endocrine-related disorders. While the company's presence may extend to other countries and regions through partnerships and collaborations, its core operations and activities predominantly center around its home country, the United States.

What significant milestones has the company Neurocrine Biosciences achieved?

Neurocrine Biosciences Inc has achieved several significant milestones. One notable milestone is the FDA approval of their product called Ingrezza®, which is the first and only treatment for adults with a neurological disorder called tardive dyskinesia. The approval of Ingrezza® marked a major breakthrough in addressing this debilitating condition. Additionally, Neurocrine Biosciences Inc successfully developed and obtained FDA approval for other innovative medications, including Orilissa® for the treatment of endometriosis and Intra-Cellular Therapies for bipolar disorder. Moreover, they have made significant progress in their research and development pipeline, working towards new treatments for various neurological and endocrine disorders. Neurocrine Biosciences Inc continues to be a leading pharmaceutical company making significant contributions to the field.

What is the history and background of the company Neurocrine Biosciences?

Neurocrine Biosciences Inc is a biopharmaceutical company headquartered in San Diego, California. Founded in 1992, Neurocrine is focused on discovering, developing, and commercializing innovative medicines for neurological and endocrine disorders. With a strong commitment to scientific excellence, the company has built a diverse portfolio of potential therapeutics addressing various highly unmet medical needs. Neurocrine has successfully brought multiple products to market, including treatments for tardive dyskinesia and endometriosis-associated pain. Their ongoing research and development efforts aim to improve the lives of patients suffering from disorders such as Parkinson's disease, uterine fibroids, and congenital adrenal hyperplasia. Neurocrine Biosciences Inc is recognized as a leading player in the biopharmaceutical industry.

Who are the main competitors of Neurocrine Biosciences in the market?

The main competitors of Neurocrine Biosciences Inc in the market include companies like AbbVie Inc., Acadia Pharmaceuticals Inc., and Amicus Therapeutics Inc. These companies operate in the biopharmaceutical industry and compete with Neurocrine Biosciences in developing and marketing innovative drug therapies. Neurocrine Biosciences Inc has established itself as a leading player in the industry, but it faces competition from these companies in terms of research, development, and commercialization of novel treatments for various medical conditions.

In which industries is Neurocrine Biosciences primarily active?

Neurocrine Biosciences Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Neurocrine Biosciences?

The business model of Neurocrine Biosciences Inc. revolves around developing and commercializing innovative treatments for neurological and endocrine-related disorders. The company focuses on discovering and advancing therapeutics that address unmet medical needs and improve patients' quality of life. Neurocrine Biosciences utilizes its expertise in research and development, clinical trials, and regulatory affairs to bring novel treatments to market. By collaborating with healthcare professionals and industry partners, the company aims to transform patient care in areas such as movement disorders, neuropsychiatric disorders, and hormonal diseases. Neurocrine Biosciences Inc.'s commitment to innovation and patient-centric solutions drives its success in the biopharmaceutical industry.

What is the P/E ratio of Neurocrine Biosciences 2024?

The Neurocrine Biosciences P/E ratio is 28.51.

What is the P/S ratio of Neurocrine Biosciences 2024?

The Neurocrine Biosciences P/S ratio is 5.17.

What is the AlleAktien quality score of Neurocrine Biosciences?

The AlleAktien quality score for Neurocrine Biosciences is 6/10.

What is the revenue of Neurocrine Biosciences 2024?

The expected Neurocrine Biosciences revenue is 2.37 B USD.

How high is the profit of Neurocrine Biosciences 2024?

The expected Neurocrine Biosciences profit is 429.34 M USD.

What is the business model of Neurocrine Biosciences

Neurocrine Biosciences Inc is an emerging biopharmaceutical company specialized in researching, developing, and marketing innovative therapies for the treatment of neurological and endocrine disorders. The company was founded in 1992 and is headquartered in San Diego, California. Neurocrine Biosciences has four main products in its pipeline, all based on innovation and research. One of these products is Ingrezza, the first FDA-approved medication for the treatment of Tardive Dyskinesia (TD) in adults. The company has also developed another medication called Orilissa, used for the treatment of endometriosis in women. Additionally, the company is working on therapies for children and specialized extracts from patients' immune systems for the treatment of severe diseases. The business model of Neurocrine Biosciences is based on developing innovative products and therapies to help patients with neurological and endocrine disorders. The company utilizes its research and development departments to identify and develop new therapies tailored to patients' needs. The company also has a wide range of collaborations and partnerships with universities and other companies worldwide to accelerate and improve its research. The company also serves various markets and target audiences to maximize its impact. Neurocrine Biosciences focuses on collaborating with hospitals, clinics, physicians, patients, and insurers to ensure that its products and therapies are accessible to all who can benefit from them. The company also dedicates significant time and resources to educate healthcare professionals and physicians to ensure that they recognize and utilize the full potential of its products. In addition to its development pipeline, the company has demonstrated a strong commitment to social responsibility. Neurocrine Biosciences is a member of the Corporate Responsibility Network (CRN), which advocates for promoting patient health and well-being and the community. The company has also adopted a sustainable business leadership policy aimed at reducing environmental impact and integrating social responsibility into all business processes. Overall, the business model of Neurocrine Biosciences is focused on innovation, research, and partnerships to provide worldwide access to innovative therapies and medications for the treatment of neurological and endocrine disorders. The company is well-positioned to tackle future challenges in the medical and pharmaceutical industry and is expected to continue to thrive in this field.

What is the Neurocrine Biosciences dividend?

Neurocrine Biosciences pays a dividend of 0 USD distributed over payouts per year.

How often does Neurocrine Biosciences pay dividends?

The dividend cannot currently be calculated for Neurocrine Biosciences or the company does not pay out a dividend.

What is the Neurocrine Biosciences ISIN?

The ISIN of Neurocrine Biosciences is US64125C1099.

What is the Neurocrine Biosciences WKN?

The WKN of Neurocrine Biosciences is 900964.

What is the Neurocrine Biosciences ticker?

The ticker of Neurocrine Biosciences is NBIX.

How much dividend does Neurocrine Biosciences pay?

Over the past 12 months, Neurocrine Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Neurocrine Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Neurocrine Biosciences?

The current dividend yield of Neurocrine Biosciences is .

When does Neurocrine Biosciences pay dividends?

Neurocrine Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Neurocrine Biosciences?

Neurocrine Biosciences paid dividends every year for the past 0 years.

What is the dividend of Neurocrine Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Neurocrine Biosciences located?

Neurocrine Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Neurocrine Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Neurocrine Biosciences from 9/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/6/2024.

When did Neurocrine Biosciences pay the last dividend?

The last dividend was paid out on 9/6/2024.

What was the dividend of Neurocrine Biosciences in the year 2023?

In the year 2023, Neurocrine Biosciences distributed 0 USD as dividends.

In which currency does Neurocrine Biosciences pay out the dividend?

The dividends of Neurocrine Biosciences are distributed in USD.

All fundamentals about Neurocrine Biosciences

Our stock analysis for Neurocrine Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neurocrine Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.